Manufacturing Intelligence: What FDA's NAM Rule Means for CMC Teams

Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.

Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.

Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.

Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.